193 related articles for article (PubMed ID: 37760788)
1. Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma.
Ashton LV; Weishaar KM; Séguin B; MacNeill AL
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760788
[TBL] [Abstract][Full Text] [Related]
2. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.
MacNeill AL; Weishaar KM; Séguin B; Powers BE
Viruses; 2018 Jul; 10(8):. PubMed ID: 30060548
[TBL] [Abstract][Full Text] [Related]
3. Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.
Ashton LV; Graham B; Afzali MF; Gustafson D; MacNeill AL
Oncolytic Virother; 2020; 9():17-29. PubMed ID: 32548076
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.
Ashton LV; Quackenbush SL; Castle J; Wilson G; McCoy J; Jordan M; MacNeill AL
Viruses; 2020 May; 12(5):. PubMed ID: 32397134
[TBL] [Abstract][Full Text] [Related]
5. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Urbasic AS; Hynes S; Somrak A; Contakos S; Rahman MM; Liu J; MacNeill AL
Am J Vet Res; 2012 Aug; 73(8):1252-61. PubMed ID: 22849686
[TBL] [Abstract][Full Text] [Related]
6. The potential of the combined use of targeted type I interferon pathway inhibitors and oncolytic viruses to treat sarcomas.
MacNeill AL
Vet Comp Oncol; 2020 Mar; 18(1):36-42. PubMed ID: 31618515
[TBL] [Abstract][Full Text] [Related]
7. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
[TBL] [Abstract][Full Text] [Related]
8. Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus.
Dryja P; Curtsinger HD; Bartee MY; Bartee E
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270180
[TBL] [Abstract][Full Text] [Related]
9. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
10. The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase.
Woo Y; Warner SG; Geha R; Stanford MM; Decarolis P; Rahman MM; Singer S; McFadden G; Fong Y
Clin Med Insights Oncol; 2021; 15():1179554921993069. PubMed ID: 33633477
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Banovic F; Tarigo J; Gordon H; Barber JP; Gogal RM
Vet Dermatol; 2019 Feb; 30(1):17-e6. PubMed ID: 30417482
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma.
Armando F; Fayyad A; Arms S; Barthel Y; Schaudien D; Rohn K; Gambini M; Lombardo MS; Beineke A; Baumgärtner W; Puff C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808256
[TBL] [Abstract][Full Text] [Related]
13. Systemic cellular viroimmunotherapy for canine high-grade gliomas.
Cloquell A; Mateo I; Gambera S; Pumarola M; Alemany R; García-Castro J; Perisé-Barrios AJ
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600663
[TBL] [Abstract][Full Text] [Related]
14. Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas.
Stinson JA; Sheen A; Momin N; Hampel J; Bernstein R; Kamerer R; Fadl-Alla B; Samuelson J; Fink E; Fan TM; Wittrup KD
Clin Cancer Res; 2023 Jun; 29(11):2110-2122. PubMed ID: 37014656
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.
Gentschev I; Adelfinger M; Josupeit R; Rudolph S; Ehrig K; Donat U; Weibel S; Chen NG; Yu YA; Zhang Q; Heisig M; Thamm D; Stritzker J; Macneill A; Szalay AA
PLoS One; 2012; 7(5):e37239. PubMed ID: 22615950
[TBL] [Abstract][Full Text] [Related]
16. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.
Nounamo B; Liem J; Cannon M; Liu J
Mol Ther Oncolytics; 2017 Sep; 6():90-99. PubMed ID: 28875159
[TBL] [Abstract][Full Text] [Related]
17. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
Omar NB; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Platt SR; Rissi DR; Shores A; Sorjonen D; Yanke AB; Gillespie GY; Chambers MR
Neurosurg Focus; 2021 Feb; 50(2):E5. PubMed ID: 33524948
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Virotherapy with Myxoma Virus.
Rahman MM; McFadden G
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936317
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Viruses for Canine Cancer Treatment.
Sánchez D; Cesarman-Maus G; Amador-Molina A; Lizano M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30373251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
